Anti-PD-1 combinations with standard of care therapies, including chemotherapy and vascular endothelial growth factor (VEGF) inhibitors have improved responses to anti-PD-1 blockade in numerous cancer types [30]. The gene discussed is VEGFA; the disease is cancer.